Tanker Market

Business

Northland Cuts Bitdeer Price Target to $25 After December Update, Maintains Bullish Stance

Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.

Jan 30, 2026

Business

Guggenheim Backs AtaiBeckley with Buy Rating, $11 Target, Citing Breakthrough Potential in Mental Health

Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.

Jan 30, 2026

Business

Geron Sees Price Target Cut to $3 by TD Cowen Ahead of Q4, But Buy Rating Stays

Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.

Jan 30, 2026

Business

Morgan Stanley Downgrades Gogo Outlook as 5G Rollout Meets Industry Uncertainty

Analysts remain divided on Gogo Inc.'s trajectory as the in-flight connectivity provider navigates its 5G network launch against a backdrop of strategic shifts and evolving satellite technology debates.

Jan 30, 2026

Business

Century Therapeutics Gains Analyst Confidence with Extended Cash Runway and Key IND Submission on Horizon

Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.

Jan 30, 2026

Business

Maxim Group Reiterates Bullish Stance on Strive (ASST), Sees 50% Upside to $1.50 Target

Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Sweetgreen Shares Slump Amid Growth Stock Sell-Off, Goldman Sachs Maintains Sell Rating

The fast-casual salad chain's stock fell sharply this week, pressured by a broader retreat in growth stocks and a reiterated sell call from Goldman Sachs, despite positive signals from the broader restaurant sector.

Jan 30, 2026

Business

Michigan Demands $23.7 Million Back from Chinese Battery Maker Gotion After Scrapped Plant Deal

Michigan's Attorney General has formally demanded the return of state funds from Gotion Inc., a Chinese battery manufacturer, following the collapse of its planned $2.4 billion facility. The move highlights growing tensions over foreign investment in U.S. strategic industries.

Jan 30, 2026

Business

Fiserv's Plunge: A Value Trap or a Turnaround Bet for 2026?

Once a fintech stalwart, Fiserv shares have cratered 70% in a year. As its 'One Fiserv' restructuring plan kicks in, investors are grappling with whether the beaten-down stock is a bargain or a warning sign.

Jan 30, 2026

Business

Beyond the Roth Hype: Why Traditional Retirement Accounts May Be the Smarter Tax Move for Many

While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.

Jan 30, 2026

Business

Amazon Announces 16,000 Job Cuts: A Strategic Pivot or Sign of Strain?

Amazon is set to eliminate 16,000 corporate roles, marking its largest workforce reduction since 2023. As the tech giant streamlines operations and doubles down on AI, investors are weighing the long-term strategy against near-term turbulence.

Jan 30, 2026

Business

OpenAI's Reported 2026 IPO: A High-Stakes Test for the AI Investment Frenzy

Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.

Jan 30, 2026

Business

Bloomin' Brands Faces Headwinds: Debt, Stagnant Sales Cloud Outlook

Shares of restaurant operator Bloomin' Brands have tumbled over 35% in six months, raising questions about its financial health and growth trajectory as analysts flag significant risks.

Jan 30, 2026

Business

Darling Ingredients' Rally Raises Eyebrows: Analysts Flag Concerns, Suggest Alternative Play

Despite a 39% surge in six months, Darling Ingredients faces scrutiny over its long-term sales decline, margin pressures, and falling profitability. Analysts point investors toward more resilient sectors.

Jan 30, 2026

Business

Walker & Dunlop's Slide: Three Red Flags for Investors and a Safer Alternative

While the S&P 500 has climbed, Walker & Dunlop shares have tumbled over 14% in six months. We analyze the underlying weaknesses in its financials and highlight a more compelling opportunity for value-focused portfolios.

Jan 30, 2026

Business

Therapeutics Sector Shows Resilience in Q3: United Therapeutics Lags as Halozyme and Biogen Outperform

A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.

Jan 30, 2026

Business

Haemonetics Gains Analyst Backing After Strategic Vivasure Buyout

Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.

Jan 30, 2026

Business

OneSeven Bolsters Leadership Amid Rapid Growth, Nears $9 Billion in Assets

The Cleveland-based RIA platform has appointed three senior executives as its assets under management soar, positioning the firm for its ambitious target of $20 billion by 2027.

Jan 30, 2026

Business

U.S. Drilling Activity Stalls Amid Mixed Signals for Oil and Gas

The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.

Jan 30, 2026